Active ingredientIstradefyllineCat. No. P-I103-001CAS 155270-99-8Family · Pharmaceutical analytical standards
Istradefylline
An adenosine A2A receptor antagonist, used together with levodopa to reduce 'off' periods in Parkinson's disease: approved in Japan in 2013 and in the United States in 2019. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Its parent molecule is caffeine, which also blocks adenosine receptors but without telling their types apart. The US FDA classes it as a 'first-in-class' medicine, with a mechanism different from that of dopaminergic drugs.
Go to the active ingredient →Active ingredientIstradefyllineCat. No. P-I103-001CAS 155270-99-8
Isotopically labelledIstradefylline-13C-d3Cat. No. P-I103-002CAS 2749234-46-4
Impurity(E)-3-(3,4-dimethoxyphenyl)acrylamideCat. No. P-I103-003CAS 14773-40-1
Impurity(Z)-IstradefyllineCat. No. P-I103-004CAS 606080-73-3
Impurity3,4-Didesmethyl IstradefyllineCat. No. P-I103-005CAS 155272-03-0
Impurity3-Desmethyl IstradefyllineCat. No. P-I103-006CAS 155272-04-1
Impurity4-Desmethyl IstradefyllineCat. No. P-I103-007CAS 160434-48-0
ImpurityIstradefylline Impurity 1Cat. No. P-I103-008
ImpurityIstradefylline Impurity 2Cat. No. P-I103-009
ImpurityIstradefylline Impurity 3Cat. No. P-I103-010
ImpurityIstradefylline Impurity 4Cat. No. P-I103-011
ImpurityIstradefylline Impurity 5Cat. No. P-I103-012
ImpurityIstradefylline Impurity 6Cat. No. P-I103-013
ImpurityIstradefylline Impurity 7Cat. No. P-I103-014
ImpurityIstradefylline Impurity 8Cat. No. P-I103-015
ImpurityIstradefylline Impurity 9Cat. No. P-I103-016
ImpurityIstradefylline Impurity 10Cat. No. P-I103-017CAS 1453190-01-6
ImpurityMethyl ethylcarbamateCat. No. P-I103-018CAS 6135-31-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.